Salt Lake City-based TheraTarget, a USTAR-funded company spun out of the University of Utah, is in a joint research collaboration agreement with Maryland-based Rexahn Pharmaceuticals, the two firms announced this morning. According to the two, TheraTarget will synthesize and supply Rexahn with polymer-drug conjugate products, for Rexahn's polymer-based nanomedicine portfolio. Financial details of the joint agreement were not disclosed. TheraTarget was founded by Dr. Jindrich (Henry) Kopecek and Dr. Hamid Ghandehari, both nanoscience researchers at the University of Utah.
Top NewsMonday, December 14, 2009
TheraTarget in Joint Research Deal